In addition, pulse MEK treatment combined with CTLA-4 blockade can prolong the survival time of KRAS-mutant tumour in mice, which may be related to T cell activation and increased CTLA-4 expression due to MEK pulse therapy. The gene discussed is KRAS; the disease is neoplasm.